Capital Fund Management (CFM)
FPRX

Capital Fund Management (CFM)’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,700
Closed -$76K – 2100
2019
Q3 		$76K Buy
+19,700
New +$108K ﹤0.01% 1616
2017
Q3 		– Sell
-13,819
Closed -$416K – 1819
2017
Q2 		$416K Sell
13,819
-82,345
-86% -$2.57M ﹤0.01% 1173
2017
Q1 		$3.48M Sell
96,164
-70,781
-42% -$3.12M 0.03% 583
2016
Q4 		$8.37M Buy
166,945
+13,265
+9% +$697K 0.07% 341
2016
Q3 		$8.07M Buy
+153,680
New +$7.34M 0.07% 317

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s FPRX Position: Q4 2019 in Review

Capital Fund Management (CFM) sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2019, closing a stake of 19,700 shares — an estimated $76K sold.

Capital Fund Management (CFM) first reported a position in FPRX in Q3 2016 and held it in 5 quarters. The position peaked at $8.37M in Q4 2016. 94 funds tracked by Wall St. Rank hold FPRX as of Q4 2019.

  • Capital Fund Management (CFM) reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 19,700 Five Prime Therapeutics, Inc. shares in Q4 2019, an estimated $76K.
  • Capital Fund Management (CFM) first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 5 quarters.
  • Capital Fund Management (CFM)'s Five Prime Therapeutics, Inc. position peaked at $8.37M in Q4 2016.
  • 94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2019.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2019, filed 13 Feb 2020.